• Revisiting Seamless 2/3 Trial for GLP-1 Agonist

  • 2025/04/28
  • 再生時間： 43 分
  • ポッドキャスト

Revisiting Seamless 2/3 Trial for GLP-1 Agonist

無料で聴く

ポッドキャストの詳細を見る

  • サマリー

  • In this episode of "In the Interim..." we revisit the ground-breaking seamless phase 2/3 clinical trial for the GLP-1 agonist, dulaglutide—better known as Trulicity. We discuss the intricacies of the adaptive trial design, and the unique features that helped expedite development by 12-18 months. Listeners will gain insight into how Bayesian algorithms and innovative statistical methods were pivotal in navigating a complex trial design, benefiting Eli Lilly's pipeline and changing the landscape of diabetes treatment.

    Key Highlights:

    • Outline of the trial design and the barriers faced during its inception in 2007-2008.
    • Explanation of the Clinical Utility Index and its role in adaptive randomization.
    • The DSMB's role and interaction with Bayesian decision-making models.
    • Simulation-based design to optimize development efficiencies.
    • Insights into the predictive power of the trial on weight loss outcomes in subsequent trials.


    Quotes:

    • "The trial was run entirely by Bayesian algorithms." – Scott Berry
    • "They believed this utility function was absolutely the right way to go forward." – Scott Berry
    続きを読む 一部表示

あらすじ・解説

In this episode of "In the Interim..." we revisit the ground-breaking seamless phase 2/3 clinical trial for the GLP-1 agonist, dulaglutide—better known as Trulicity. We discuss the intricacies of the adaptive trial design, and the unique features that helped expedite development by 12-18 months. Listeners will gain insight into how Bayesian algorithms and innovative statistical methods were pivotal in navigating a complex trial design, benefiting Eli Lilly's pipeline and changing the landscape of diabetes treatment.

Key Highlights:

  • Outline of the trial design and the barriers faced during its inception in 2007-2008.
  • Explanation of the Clinical Utility Index and its role in adaptive randomization.
  • The DSMB's role and interaction with Bayesian decision-making models.
  • Simulation-based design to optimize development efficiencies.
  • Insights into the predictive power of the trial on weight loss outcomes in subsequent trials.


Quotes:

  • "The trial was run entirely by Bayesian algorithms." – Scott Berry
  • "They believed this utility function was absolutely the right way to go forward." – Scott Berry
続きを読む 一部表示

Revisiting Seamless 2/3 Trial for GLP-1 Agonistに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。